Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
QDEL | US
-0.29
-0.72%
Healthcare
Diagnostics & Research
30/06/2024
15/10/2024
40.20
40.20
40.72
39.88
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs Transfusion Medicine Point-of-Care and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests which measure proteins as they act as antigens in the spread of disease antibodies in the immune response spurred by disease or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices hospitals clinical laboratories reference laboratories urgent care clinics universities retail clinics pharmacies wellness screening centers blood banks and donor centers as well as for individual non-professional and over-the-counter use. It operates in North America Europe the Middle East Africa China and internationally. The company was founded in 1979 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
23.4%1 month
29.9%3 months
45.3%6 months
43.3%-
13.23
0.89
0.87
0.41
7.61
1.94
7.19
589.70M
2.76B
2.76B
-
-4.66
-77.10
-4.20
-45.48
5.16
9.08
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
5.89
Range1M
7.74
Range3M
16.27
Rel. volume
1.03
Price X volume
28.81M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twist Bioscience Corporation | TWST | Diagnostics & Research | 46.31 | 2.71B | -0.71% | n/a | 17.75% |
Guardant Health Inc | GH | Diagnostics & Research | 21.56 | 2.65B | 1.03% | n/a | -83144.02% |
Myriad Genetics Inc | MYGN | Diagnostics & Research | 23.98 | 2.18B | -4.46% | n/a | 0.00% |
Soleno Therapeutics Inc | SLNO | Diagnostics & Research | 54.15 | 2.10B | 0.54% | n/a | 0.11% |
NeoGenomics Inc | NEO | Diagnostics & Research | 14.03 | 1.80B | 1.59% | n/a | 66.22% |
CareDx Inc | CDNA | Diagnostics & Research | 26.35 | 1.39B | -15.84% | n/a | 11.88% |
CASTLE BIOSCIENCES INC | CSTL | Diagnostics & Research | 33.48 | 928.63M | -2.28% | n/a | 5.94% |
Fulgent Genetics Inc | FLGT | Diagnostics & Research | 20.26 | 613.81M | -0.44% | n/a | 1.18% |
Celcuity Inc | CELC | Diagnostics & Research | 15.77 | 583.97M | 4.02% | n/a | 54.62% |
Pacific Biosciences of California Inc | PACB | Diagnostics & Research | 2.1 | 572.31M | 2.44% | n/a | 187.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 23.53 | 2.93B | 2.22% | 87.62 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 54.01 | 2.55B | 0.86% | 21.48 | 76.47% |
Lions Gate Entertainment Corp | LGF-A | Media - Diversified | 7.55 | 1.68B | -0.66% | n/a | 28882.88% |
Lions Gate Entertainment Corp | LGF-B | Media - Diversified | 6.7 | 1.68B | -0.74% | n/a | 28882.88% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 39.59 | 1.65B | -0.58% | 39.88 | 64.69% |
Janus International Group Inc. | JBI | Building Products & Equipment | 10.4 | 1.51B | 1.76% | 11.40 | 116.21% |
AMC Entertainment Holdings Inc | AMC | Media - Diversified | 4.15 | 1.50B | 0.73% | n/a | -511.14% |
REV Group Inc | REVG | Recreational Vehicles | 28.12 | 1.46B | 0.93% | 6.37 | 63.13% |
Steelcase Inc | SCS | Building Products & Equipment | 12.95 | 1.44B | -0.23% | 11.84 | 65.47% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.96 | 1.25B | -1.14% | n/a | -571.93% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 7.61 | 12.33 | Cheaper |
Ent. to Revenue | 1.94 | 39.67 | Cheaper |
PE Ratio | - | 39.96 | - |
Price to Book | 0.89 | 76.13 | Cheaper |
Dividend Yield | - | 1.19 | - |
Std. Deviation (3M) | 45.29 | 62.86 | Lower Risk |
Debt to Equity | 0.87 | -14.36 | Expensive |
Debt to Assets | 0.41 | 0.34 | Expensive |
Market Cap | 2.76B | 13.17B | Emerging |